Laboratorios Farmaceuticos ROVI (ROVI.MC) Osake Kurssi
Laboratorios Farmaceuticos ROVI Kurssi
Liikevaihto on kasvanut 12,6 % vuodessa viimeisten 19 vuoden aikana 743,48 M EUR:een. Osakekohtainen tulos on kasvanut 19,0 % vuodessa viimeisten 19 vuoden aikana. Laboratorios Farmaceuticos ROVIn nettomarginaali on nyt 18,9 %, laskenut 23,6 %:sta muutama vuosi sitten. Laboratorios Farmaceuticos ROVIn osinkotuotto on tällä hetkellä noin 1,61 %. Jakosuhde on noin 34 % tuloksesta. Osinko on kasvanut 15,7 % vuodessa viimeisten 17 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 85,07 EUR, eli yli nykyhintaa 46,3 %. 16 analyytikosta 13 suosittaa ostoa — kokonaiskonsensus on Osta.
Laboratorios Farmaceuticos ROVI osakekurssi
Laboratorios Farmaceuticos ROVI liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Laboratorios Farmaceuticos ROVI -osakkeesta
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Analyytikot asettavat tällä hetkellä Laboratorios Farmaceuticos ROVI-osakkeelle keskimääräisen tavoitehinnan 84,26 EUR (mediaani: 85,07 EUR), mikä merkitsee +44,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.
Laboratorios Farmaceuticos ROVI Analyytikkojen kursstavoitteet 2026
16 analyytikkoa arvioi tällä hetkellä Laboratorios Farmaceuticos ROVI-osaketta: 13 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Laboratorios Farmaceuticos ROVI-yhtiöltä 773,24 M EUR liikevaihtoa ja 2,72 EUR osakekohtaista tulosta.
Laboratorios Farmaceuticos ROVI Analyytikkojen kursstavoitteet 2026
Laboratorios Farmaceuticos ROVI-osake (ROVI.MC) on listattuna 9 pörssissä, muun muassa: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
odotettu liikevaihto Laboratorios Farmaceuticos ROVI on 773,24 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Laboratorios Farmaceuticos ROVI on 139,19 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Laboratorios Farmaceuticos ROVI:n hinta-voitto-suhde (P/E) on tällä hetkellä 21,37. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Laboratorios Farmaceuticos ROVI-osakkeen arvostusta.
Laboratorios Farmaceuticos ROVI:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,85. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Laboratorios Farmaceuticos ROVI-osakkeen arvostuskennuslukuna.
Laboratorios Farmaceuticos ROVI:n Eulpool-laatuscore on 6/10.
Laboratorios Farmaceuticos ROVI:n ISIN on ES0157261019. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Laboratorios Farmaceuticos ROVI:n WKN on A0M0GQ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Laboratorios Farmaceuticos ROVI:n ticker on ROVI.MC. Tämä pörssinoteeraus käytetään Laboratorios Farmaceuticos ROVI-osakkeiden kauppaan pörssissä.
Laboratorios Farmaceuticos ROVI osake
Laboratorios Farmaceuticos ROVI vertaisryhmä
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
Kaikki tunnusluvut ja syvällinen analyysi Laboratorios Farmaceuticos ROVI:sta
Meidän osakeanalyysimme Laboratorios Farmaceuticos ROVI-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Laboratorios Farmaceuticos ROVI:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: